Pasi Jänne

Pasi is the Director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute.

His research combines laboratory-based studies with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations, and findings from his studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients. He led the first-in man clinical trial of the mutant selective EGFR inhibitor osimertinib which was approved by the Food and Drug Administration in 2015. Pasi has received several awards for his research, including from Uniting Against Lung Cancer, American Lung Association, the Bonnie J. Addario Lung Cancer Foundation, the American Association of Cancer Research , the European Society of Medical Oncology and the American Society of Clinical Oncology. In 2017 he was awarded an American Cancer Society Clinical Research Professorship. Pasi earned his Masters Degree in clinical investigation from Harvard University and his MD and PhD from the School of Medicine at the University of Pennsylvania. He completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston.